Post-marketing Surveillance of Spesolimab I.V. Infusion in Improvement of Generalized Pustular Psoriasis (GPP) With Acute Symptoms in Japan
Latest Information Update: 18 Mar 2025
At a glance
- Drugs Spesolimab (Primary)
- Indications Generalised pustular psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 13 Mar 2025 Status changed from recruiting to active, no longer recruiting.
- 25 Jul 2023 Status changed from not yet recruiting to recruiting.
- 11 Jul 2023 Planned initiation date changed from 1 Jul 2023 to 1 Aug 2023.